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Neuroplasticity may have a core role in the pathophysiology of major depressive disorder (MDD), a concept supported by
experimentalstudiesthatfoundthatexcessivecortisolsecretionand/orexcessiveproductionofinﬂammatorycytokinesimpairs
neuronal plasticity and neurogenesis in the hippocampus. The objective of this study was to examine how changes in the
glucocorticoid and inﬂammatory systems may affect hippocampal volumes in MDD. A multimodal approach with structural
neuroimaging of hippocampus and amygdala, measurement of peripheral inﬂammatory proteins interleukin (IL)-6 and C-reactive
protein (CRP), glucocorticoid receptor (GR) mRNA expression, and expression of glucocorticoid-inducible genes
(glucocorticoid-inducible genes Leucin Zipper (GILZ) and glucocorticoid-inducible kinase-1 (SGK-1)) was used in 40 patients
with MDD and 43 healthy controls (HC). Patients with MDD showed smaller hippocampal volumes and increased inﬂammatory
proteins IL-6 and CRP compared with HC. Childhood maltreatment was associated with increased CRP. Patients with MDD, who
had less expression of the glucocorticoid-inducible genes GILZ or SGK-1 had smaller hippocampal volumes. Regression
analysis showed a strong positive effect of GILZ and SGK-1 mRNA expression, and further inverse effects of IL-6 concentration,
on hippocampal volumes. These ﬁndings suggest that childhood maltreatment, peripheral inﬂammatory and glucocorticoid
markers and hippocampal volume are interrelated factors in the pathophysiology of MDD. Glucocorticoid-inducible genes GILZ
and SGK-1 might be promising candidate markers for hippocampal volume changes relevant for diseases like MDD. Further
studies need to explore the possible clinical usefulness of such a blood biomarker, for example, for diagnosis or prediction of
therapy response.
Translational Psychiatry (2012) 2, e88; doi:10.1038/tp.2012.14; published online 13 March 2012
Introduction
Major depressive disorder (MDD) is a serious psychiatric
disorder with a high relapse rate and lifetime prevalence of
15%.
1 Despite the experimental ﬁndings involving neuro-
plasticity in the pathophysiology of MDD,
2 to date this work
has not been translated into the clinical setting in terms of
elucidating a causal role for stress and inﬂammatory
cytokines in mediating hippocampal changes. In the clinic,
it is well established that depressed patients hypersecrete
cortisol,
3 have impaired glucocorticoid receptor (GR) func-
tioning,
4 have increased circulating concentrations of
inﬂammatory cytokines
5 and C-reactive protein (CRP)
6
and have reduced hippocampal volumes.
7 It has been
shown that hippocampal volume reduction is associated
with exposure to stress
7 and that it is inﬂuenced by genetic
variation.
8
The ﬁrst study that assessed the association between
hippocampalvolumesandcortisolmeasureswaspublishedby
Lupienetal.
9Thislongitudinalstudyconducted over5years in
older adults demonstrated a correlation over time between
cortisol levels and hippocampal volume changes. The total
hippocampal volume of six subjects with increasing or high
cortisol levels was signiﬁcantly reduced by 14%in comparison
with that of ﬁve subjects with decreasing/moderate cortisol
levels and the degree of hippocampal atrophy correlated
strongly with both the degree of cortisol elevation over time
and current basal cortisol levels. Since then, there is some
further evidence that reduced hippocampal volumes are
associated with higher continuous cortisol secretion during
the day
10–12 and with abnormal blunted cortisol responses
during awakening or during stress tests.
13–16 However, data
are inconsistent
17,18 and heterogeneous, even between the
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In this context, the glucocorticoid-inducible genes Leucin
Zipper (GILZ)and serum and glucocorticoid-inducible kinase-1
(SGK-1) are target genes activated by GR activation, and their
expression has been shown to be disrupted in the hippocam-
pus as a result of hypercortisolemia.
20 In addition, a recent
study demonstrated a relationship between downregulation of
GILZ and an enhanced inﬂammatory proﬁle in microglia
isolated from mice subjected to a chronic stress regimen.
21
Considering the well-established inverse relationship between
GR function and inﬂammation,
4 we examined GR expression
and expression of the glucocorticoid-inducible genes GILZ and
SGK-1 in tandem with inﬂammatory measures.
The aim of this study was to determine whether glucocorti-
coid-inducible genes GILZ and SGK-1 and inﬂammation are
related to hippocampal volumes in patients with MDD.
Moreover, we wanted to determine how this pathway would
be inﬂuenced by early childhood adversity.
Participants and methods
Participants. The study included 40 adult patients with MDD
from the mental health services of the Adelaide and Meath
Hospital, incorporating the National Children’s Hospital, Dublin
or St James’s Hospital, Dublin. The diagnosis of these patients
with MDD was a clinical diagnosis based on DSM-IV criteria
and conﬁrmed by an independent psychiatrist using the SCID
interview. Forty-three healthy subjects (HC) from the local
community were recruited and the groups were balanced for
age and sex (Table 1). Fourteen patients received mono-
therapy with selective serotonin reuptake inhibitor and 15 with a
dual acting antidepressant (mirtazapine or venlafaxine). Eleven
patients were medication-freew h e nt h e yw e r et r a n s f e r r e dt o
our service and were investigated before restarting antide-
pressant therapy. Antipsychotics or mood stabilizers were ex-
clusion criteria. Other exclusion criteria were age o18 or 465,
history of neurological or comorbid psychiatric disorders (axis I
or axis II), other severe medical illness, head injury or sub-
stance abuse. Demographic variables, inclusion and exclusion
criteria were documented using a standardized questionnaire
and through a structured interview by a psychiatrist.
Written informed consent was obtained from all participants
after being given detailed description of the study, which was
designed and performed in accordance to the ethical
standards laid out by the Declaration of Helsinki and was
approved by the ethics committee of St James and the
Adelaide and Meath Hospitals, Dublin.
Rating instruments. Self- and observer-rated scales were
also ﬁlled out for all participants included in the study. The
following rating scales were used: the Hamilton Rating Scale
for Depression,
22 Beck’s Depression Inventory,
23 Childhood
Trauma Questionnaire (CTQ)
24 and the Structured Clinical
Interview for DSM-IV (SCID-II) personality questionnaire.
CTQ is a standardized self-report instrument that assesses
ﬁve types of childhood maltreatment: emotional, physical, and
sexual abuse, and emotional and physical neglect. Reliability
and validity of the CTQ have been established, including
measures of convergent and discriminative validity from
structured interviews, stability over time and corroboration.
25
Based on the cut-off values for traumatization, we determined
participants with and without early childhood adversity.
Subjects scoring above the cut-off in at least one of the
items were those with childhood adversity.
25
Magnetic resonance imaging T1 data acquisition. Magnetic
resonance images were obtained with a Philips Achieva MRI
Table 1 Demographic data and ELA for patients with MDD and healthy controls
Patients (N¼40) Controls (N¼43) Stat (P-value)
Age (years) 41.4 (10.9) 37.0 (13.7) t¼1.6, df¼1,81, (P¼0.1)
Gender (female/male) 24/16 25/18 w
2¼0.03, (P¼0.86)
Height (cm) 171.9 (8.0) 172.3 (10.4) t¼ 0.19, df¼1,81, (P¼0.85)
Weight (kg) 75.6 (15.1) 70.9 (16.0) t¼1.4, df¼1,81, (P¼0.18)
Alcohol (units) 3.9 (6.0) 5.0 (6.2) t¼ 0.8, df¼1,81, (P¼0.40)
Hamilton depression score 28.0 (6.5) 2.7 (2.9) t¼26.0, df¼1,81, (Po0.001)
Childhood maltreatment total 48.1 (21.7) 31.1 (5.7) t¼4.9, df¼1,81, (Po0.001)
Age of onset 25.1 (12.4)
Cumulative illness duration 9.8 (10.1)
Medication (free/SSRI /dual acting/valdoxan) 11/14/15
Hippocampus left (ml) 3.40 (0.49) 3.65 (0.41) F¼6.4, df¼1,79, (P¼0.013)
Hippocampus right (ml) 3.56 (0.50) 3.81 (0.45) F¼5.8, df¼1,79, (P¼0.019)
Amygdala left (ml) 1.62 (0.22) 1.68 (0.23) F¼1.5, df¼1,79, (P¼0.22)
Amygdala right (ml) 1.67 (0.20) 1.70 (0.21) F¼0.3, df¼1,79, (P¼0.57)
CRP 2.7 (3.0) 1.4 (1.8) Mann–Whitney U,(Z¼2.9, P¼0.004)
IL-6 13.3 (15.9) 9.9 (14.8) Mann–Whitney U,( Z¼2.1, P¼0.04)
GILZ mRNA 0.91 (0.24) 0.99 (0.25) Mann–Whitney U,( Z¼1.4, P¼0.16)
SGK-1 mRNA 0.96 (0.35) 1.0 (0.37) Mann–Whitney U,( Z¼0.44, P¼0.66)
GR mRNA 1.0 (0.25) 1.0 (0.18) Mann–Whitney U,( Z¼0.36, P¼0.72)
Abbreviations: ANCOVA, analysis of covariance; CRP, C-reactive protein; CTQ, Childhood Trauma Questionnaire; ELA, early life adversity; IL, interleukin; GILZ,
glucocorticoid-inducible genes Leucin Zipper; GR, glucocorticoid receptor; MDD, major depressive disorder; SGK-1, serum and glucocorticoid-inducible kinase-1;
SSRI, selective serotonin reuptake inhibiter.
Depicted are demographic variables age, gender, height, weight and actual alcohol consumption. Moreover, clinical data depression severity measured with the
Hamilton Depression Rating Scale, childhood maltreatment derived as total score from the CTQ, whole hippocampal and amygdala volumes and inﬂammation
markers are indicated for patients and controls. Demographic data were tested by Student’s t-test (gender with w
2 test), hippocampal and amygdala volumes
were subjects to ANCOVA using group as independent factor and age as well as total brain volume as covariates and inﬂammation markers were tested using
Mann–Whitney U-test.
mRNA expression and hippocampus in depression
T Frodl et al
2
Translational Psychiatryscanner (Philips Medical System, Netherland BV, Veenphuis
4–6, 5684 PC Best, The Netherlands) operating at 3 Tesla. A
sagittal T1 three-dimensional turbo ﬁeld echo was used to scan
all participants (repetition time user deﬁned of 8.5ms; echo time
user deﬁned of 3.9ms; total acquisition time of 7min; ﬁeld of
view of foot to head: 256mm, anterior to posterior: 256mm,
right to left: 160mm; and a matrix of 256 256). Slice thickness
was 1mm and voxel size was 1 1 1mm. All data sets were
realigned and resampled three-dimensionally in the anterior
commissure to posterior commissure line, according to the
coordinates of Talairach, with the software program BRAINS2
(Brain Research: Analysis of Images, Networks and Systems,
University of Iowa, USA). The program BRAINS2 allowed the
regions of interest
26 to be simultaneously controlled on sagittal,
coronal and transverse sections simultaneously.
Deﬁnition of hippocampal and amygdala formation. We
used manual tracing of the bilateral hippocampal and
amygdala structure with the help of the software BRAINS2
as we have previously described (Figure 1).
27 Additionally,
we divided the hippocampal structure into three parts: the
head, the body and the tail according to well-established
methods.
28,29 The amygdala tracing is described in detail
elsewhere.
30 The evaluating and tracing researcher (Angela
Carballedo for hippocampus, Karim Saleh for amygdala) were
blind to participant status. The hippocampus and amygdala
were outlined manually using a mouse-driven cursor. To
determine inter-rater reliability, 10 brains were randomly
chosen and regions of interests determined independently by
two raters. The intra-class correlation for inter-rater reliability
was high (left hippocampus: ricc¼0.92, right hippocampus:
ricc¼0.88, left head: ricc¼0.98, right head: ricc¼0.88, left
body: ricc¼0.87, right body: ricc¼0.90, left tail: ricc¼0.78,
right tail: ricc¼0.79, left amygdala: ricc¼0.85, right
amygdala: ricc¼0.91) (Supplementary Methods).
Measurement of blood inﬂammatory markers and
expression of GR and glucocorticoid-inducible genes
Blood sampling. A 10ml blood sample was taken from each
subject in the early afternoon before magnetic resonance
image scanning into a heparinized vacutainer and was
centrifuged to generate plasma. Plasma was stored at
 801C until inﬂammatory markers were measured. A
second blood sample (2.5ml) was taken into a PAXgene
blood RNA tube and used for whole blood RNA isolation and
the PAXgene tube was stored at  201C for 48h and then
moved to  801C until RNA extraction was performed. All
bloods were taken to the freezer within 1h after acquisition.
All samples were processed in the same batch with respect
to the following methods.
Plasma IL-6 and CRP measurements. Plasma interleukin
(IL)-6 was measured using an ELISA MAX Deluxe kit
(Biolegend, Cambridge, UK), and plasma CRP concen-
trations were measured using a CRP ELISA DuoSet (R&D
systems, Abingdon, UK) and these immunoassays were
performed according to the manufacturer’s instructions.
Real-time PCR analysis of mRNA expression of GR, GILZ
and SGK-1 in whole blood samples. RNA isolation was
performed using a PAXgene blood RNA kit (Qiagen, West
Sussex, UK) and was followed by DNAase treatment to
remove contaminating genomic DNA as previously
described.
31 Following RNA quantiﬁcation and equalization,
complementary DNA was synthesized using a cDNA archive
kit (Applied Biosystems, Warrington, UK). Gene expression
analysis was conducted using real-time PCR employing
Taqman Gene Expression Assays (Assay IDs: GR:
Hs00353740_m1; GILZ: Hs00608272_m1; SGK-1:
Hs00178612_m1; Applied Biosystems) and glyceraldehyde
3-phosphate dehydrogenase served as endogenous control.
PCR was performed using ABI’s universal cycling conditions
on the StepOnePlus Real-Time PCR system (see
Supplementary Methods for more detailed information).
Statistics. All statistical analysis were considered to be
signiﬁcant if Po0.05. Morphometric measurements in both
groups were normally distributed (using Kolmogorov–Smirnov
test) and their variances were homogenous (using Levene’s
test). Correlations between blood markers are indicated in
Supplementary Methods 1. We explored associations
between CRP and IL-6 with the other variables using
regression analysis with CRP, IL-6 as dependent variables
and age, diagnostic group, GR mRNA, GILZ mRNA, SGK-1
mRNA and early life adversity as independent factors.
Hippocampal volumes were subjected to an omnibus
analysis of covariance (ANCOVA) to assess the main and
interaction effects of the within-subjects factor hemisphere
Figure 1 Hippocampus and amygdala tracing: hippocampal head is delineated from the amygdala.
mRNA expression and hippocampus in depression
T Frodl et al
3
Translational Psychiatry(left, right) and subregion (head, body, tail), and the between-
subjects factor diagnostic group (MDD, healthy controls (HC))
and GILZ mRNA expression (low GILZ mRNA, high GILZ
mRNA). Left and right amygdala volumes were subjected to
similar ANCOVAs without the factor subregions. In the same
way, ANCOVAs were calculated using SGK-1, GR, IL-6 and
CRP instead of GILZ. Signiﬁcant interactions were further
evaluated with SIDAK–Bonferroni post-hoc tests. A median
split was used here to obtain low versus high mRNA
expression. As this would change a continuous variable into
a categorical variable, we also applied regression analysis as
described below.
Moreover, to test which of the inﬂammation factors or
glucocorticoid factors inﬂuenced hippocampal or amygdala
volumes regression analysis was used with hippocampal or
amygdala volumes as dependent variables and childhood
maltreatment, age, Il-6 concentration, GR mRNA expression,
SGK-1 (or GILZ) mRNA expression as independent factors.
As signiﬁcant interactive effects were found between
group (patients, controls) and SGK-1 and GILZ mRNA
expression the regression analysis were also carried out
within the group of patients with depression and the group of
HC separately.
Results
Depressed (MDD) patients did not differ in demographic
variablesage,gender,weightfromHC(Table1).IL-6(Z¼2.1,
P¼0.04); and CRP (Z¼2.9, P¼0.004) concentrations were
higher in patients with MDD compared with HC. GR, SGK-1
and GILZ mRNA did not differ between groups.
CRP or IL-6. In the regression analysis, a signiﬁcant effect
was detected for diagnostic group (patients with MDD, HC)
on CRP; with patients with MDD showing higher CRP levels
compared with controls (Fchange¼5.4, rsquare¼0.063,
df¼1,79, P¼0.023). Independent of diagnosis there was
an additional effect of childhood maltreatment on CRP
(Fchange¼4.4, rsquarechange¼0.050, df¼1,78,
P¼0.039). Age, GR, GILZ or SGK-1 mRNA did not show
signiﬁcant effects.
For IL-6, no signiﬁcant effect was seen in the regression
analysisforgroup.However,therewasatrendforasigniﬁcant
effect of childhood maltreatment on IL-6 (Fchange¼2.9,
rsquarechange¼0.035, df¼1,78, P¼0.09). A further effect
was detected for age (Fchange¼2.9, rsquarechange¼0.1,
df¼1,76, P¼0.041). The variables GR mRNA or GILZ
(SGK-1) mRNA did not show signiﬁcant effects.
GILZ or SGK-1 mRNA expression. Next, we investigated
whether expression of glucocorticoid-inducible genes had a
signiﬁcant effect on hippocampal volumes in an ANOVA with
hippocampal volumes as dependent variables and the within-
subjects factors hemisphere (left, right) and subregion (head,
body, tail), and the between-subjects groups (patients,
controls) and GILZ mRNA (high, low) (SGK-1, GR mRNA,
respectively).
Signiﬁcant smaller hippocampal volumes were found for
patientswith MDD compared with controls (F¼8.5, df¼1,77,
P¼0.005). No signiﬁcant effects or interactions were found
for the factors subregions or hemisphere indicating that the
signiﬁcantresultsapplytothewholehippocampus.Therewas
a signiﬁcant interaction between diagnostic group and GILZ
mRNA (high versus low expression (F¼4.0, df¼1,77,
P¼0.049)). Post-hoc Sidak–Bonferroni test showed that
patients with MDD and low GILZ mRNA concentration had
smaller hippocampal volumes than HC with low GILZ mRNA
concentration (M¼ 0.47, P¼0.003, Sidak corrected) and
HC with high GILZ mRNA concentration (M¼ 0.41,
P¼0.007, Sidak corrected) (Figure 2).
AsGILZmRNAandSGK-1mRNAwerehighlycorrelatedto
each other, we also expected these effects in the other
mRNAs. A signiﬁcant interactive effect was also seen for
diagnostic groups and SGK-1 mRNA (high versus low
expression (F¼4.6, df¼1,77, P¼0.035)). Post-hoc test
showed that patients with MDD and low SGK-1 mRNA
concentration had smaller hippocampal volumes compared
with patients with MDD and high SGK-1 mRNA concentration
(M¼ 0.51, P¼0.001, Sidak corrected), HC with low SGK-1
mRNA concentrations (M¼ 0.34, P¼0.066, Sidak cor-
rected), and HC with high SGK-1 mRNA concentrations
(M¼ 0.42, P¼0.006, Sidak corrected). No signiﬁcant
interaction was found between GR mRNA group and
diagnostic group (F¼0.02, df¼1,77, P¼0.9).
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Figure 2 Stratiﬁcation of patients with major depressive disorder (MDD) and
healthy controls (HC) by glucocorticoid-inducible genes Leucin Zipper (GILZ)
mRNA. Hippocampal volumes (left (a) and right (b)) are smaller in patients with
MDD and low GILZ mRNA concentration compared with HC with either high or low
GILZ mRNA. **Po0.01.
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Translational PsychiatryAmygdala volumes were not signiﬁcantly different between
patients with MDD and HC (F¼1.3, df¼1,77, P¼0.26).
There was a trend for larger amygdala volumes in participants
with higher GILZ mRNA expression (F¼3.9, df¼1,77,
P¼0.052) or respectively with higher SGK-1 mRNA expres-
sion (F¼3.8, df¼1,77, P¼0.054) compared with those with
lower expressions. GR mRNA did not have a signiﬁcant effect
on amygdala volumes (F¼0.07, df¼1,77, P¼0.78). A
signiﬁcant interactive effect was found between diagnostic
group and SGK-1 mRNA expression (F¼4.2, df¼1,77,
P¼0.043). Post-hoc signiﬁcant larger amygdala volumes
were detected in HC with high SGK-1 mRNA expression
compared with HC with low SGK-1 mRNA expression
(M¼1.7, P¼0.029, Sidak corrected). No signiﬁcant interac-
tion was found between diagnostic groups and GR mRNA or
GILZ mRNA.
Stratiﬁcation with inﬂammatory markers. The ANCOVA
showed no signiﬁcant main effect of IL-6 (F¼0.03, df¼1,77,
P¼0.87) and no interactive effect between IL-6 and diagnosis
(F¼0.29, df¼1,77, P¼0.59) on hippocampal volumes. No
signiﬁcant effect was found for CRP (F¼0.08, df¼1,77,
P¼0.78). No signiﬁcant interaction was found between
diagnostic groups and CRP groups (F¼1.6, df¼1,77,
P¼0.21).
Amygdala volumes were signiﬁcantly larger in subjects with
high IL-6 concentrations compared with those with low IL-6
concentrations (F¼6.2, df¼1,77, P¼0.015). No effects
were found for high versus low CRP concentration (F¼0.5,
df¼1,77, P¼0.48). No signiﬁcant interactions were detected
between diagnostic groups and inﬂammatory proﬁle.
Regression model. In the whole group of patients and
controls, a signiﬁcant effect of diagnostic group was seen on
left hippocampal volumes in the regression analysis
(Fchange¼9.9, rsquarechange¼0.11, df¼1,79, P¼0.002).
GILZ mRNA further showed a trend to inﬂuence left hippo-
campal volumes independent of diagnosis (Fchange¼3.1,
rsquarechange¼0.034, df¼1,78, P¼0.08). A signiﬁcant
effect of diagnostic group was also seen on right hippo-
campal volumes (Fchange¼7.6, rsquarechange¼0.087,
df¼1,79, P¼0.007). GILZ mRNA did not inﬂuence right
hippocampal volumes further (Fchange¼1.8, rsqua-
rechange¼0.021, df¼1,78, P¼0.18). No effect was seen
for childhood maltreatment on either right (Fchange¼0.45,
rsquarechange¼0.005, df¼1,77, P¼0.50) or left (Fchange¼
0.26, rsquarechange¼0.003, df¼1,77, P¼0.61) hippo-
campal volume or for the variables GR mRNA, lL-6
and CRP.
As there was a signiﬁcant interactive effect of GILZ (SGK-1
mRNA respectively) with diagnostic groups in the ANOVA, we
analyzed the regression model separately within groups. In
the patient group, the regression model was signiﬁcant for the
left (F¼2.6, df¼1,38, P¼0.037) and the right (F¼2.4,
df¼1,72, P¼0.048) hippocampus. The regression analysis
found a signiﬁcant effect of GILZ mRNA expression on left
(b¼0.59, t¼3.4, P¼0.002) and right (b¼0.57, t¼3.3,
P¼0.003) hippocampal volumes in the groups of patients
(Figure 3, Table 2). IL-6 signiﬁcantly negatively affected the
left (b¼ 0.44, t¼2.1, P¼0.044) and right (b¼ 0.44,
t¼2.1, P¼0.046) hippocampus. No signiﬁcant further effects
of CRP, age or childhood maltreatment, or GR mRNA were
seen.Theregressionanalysisfoundalsoasigniﬁcanteffectof
Patients with MDD
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Figure 3 Association between hippocampal volumes and glucocorticoid-inducible genes Leucin Zipper (GILZ) mRNA. Smaller GILZ mRNA concentration is associated
with smaller hippocampal volumes in patients with major depressive disorder (MDD) (upper row), but not in healthy controls (lower row).
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Translational PsychiatrySGK-1 mRNA expression on left (b¼0.46, t¼2.6, P¼0.014)
and right (b¼0.44, t¼2.5, P¼0.017) hippocampal volumes
in the groups of patients.
In the healthy group, no signiﬁcant associations were
detected between inﬂammatory factors, age or GR mRNA
expression.
There was not a signiﬁcant effect of any of these variables
on amygdala volumes in the regression analysis.
Medication effect. Including medication status (none,
selective serotonin reuptake inhibitors, dual) in the analysis
did not change the results. There was no signiﬁcant effect of
medication status on hippocampal volumes (F¼0.94,
df¼2,37, P¼0.40), on amygdala volumes (F¼0.49,
df¼2,37, P¼0.62), CRP (F¼1.9, df¼2,37, P¼0.16), IL-6
(F¼0.53, df¼2,37, P¼0.59), GILZ mRNA (F¼0.28,
df¼2,37, P¼0.76) or SGK1 mRNA (F¼1.9, df¼2,37,
P¼0.16).
Discussion
This is the ﬁrst study that sets the inﬂammatory state, as
assessed by measuring concentrations of CRP and the
pro-inﬂammatory cytokine IL-6, and glucocorticoid status
measured using mRNA expression of the GR and the
glucocorticoid-inducible genes (GILZ and SGK-1) as well as
hippocampus and amygdala into a cohesive pathophysiolo-
gical human model. There are several novel and remarkable
ﬁndings that should be highlighted. The smaller hippocampal
volumes in patients with MDD were mainly seen in those
patients who had less expression of GILZ mRNA, or SGK-1
mRNA respectively, as a marker of reduced activation of the
glucocorticoid system compared with those with higher GILZ
mRNA expression. In the patients, GILZ and SGK-1 mRNA
was positively correlated with hippocampal volumes indicat-
ing that in depression the status of the glucocorticoid system
may be coupled with hippocampal volumes.
It is noteworthy that a recent study in mice showed that
repeated social defeat stress reduced mRNA expression
of the glucocorticoid-responsive genes including GILZ in
microglia
21 indicating the involvement of GILZ in stress-
related diseases like depression or anxiety disorders.
Moreover, it has been suggested that glucocorticoid resis-
tance may contribute to the inﬂammatory proﬁle observed in
MDD.
32 In this study, however, we could not ﬁnd an
association between GILZ or SGK-1 mRNA expression and
inﬂammatory state.
Nevertheless,theglucocorticoidsystemhasa centralrole in
the pathophysiology of MDD and there is mounting evidence
that speciﬁc neuronal circuits, particularly in the developing
brain,are damaged byenvironmentalstressinducingchanges
in the hypothalamic–pituitary–adrenal axis and inﬂammatory
pathways.
33 Stress-related hypercortisolemia leads to central
downregulation of GRs
34 and also to glucocorticoid resistance
in peripheral immune cells.
32 In this study, we found evidence
that reduced expression of glucocorticoid-inducible genes in
patients with MDD, suggesting glucocorticoid resistance, are
associated with smaller hippocampal volumes. Such an
association might point toward a long-term effect during life,
which then might result in smaller hippocampal volumes and
glucocorticoid resistance. Thus, both the small hippocampal
volume and the low expression of glucocorticoid-inducible
genes might be a correlate of vulnerability for depression and
this would be in line with smaller hippocampal volumes in
subjects at risk for depression.
35
This is in line with experimental animal and human studies
showing the negative effects of chronic exposure to stress
and/or adversity on the developing brain. In animal studies,
stress leads to reductions in the total volume of the
hippocampus, atrophy and loss of neurons in the hippocam-
pus.
36 A recent study in a sample of patients with ﬁrst onset
psychosis reported that increased IL-6 expression, and
increased salivary cortisol levels predicted smaller hippocam-
pal volumes; and that a history of childhood maltreatment was
related to current inﬂammatory markers.
37
Increased circulating concentrations of CRP
6 and inﬂam-
matory cytokines such as IL-6
5 are well established in MDD
Table2 Regressionanalysisforleftandrighthippocampalvolumes asdependent factorsandtheindependent factorsGLIZ mRNA,GRmRNA,IL-6,CRP, childhood
maltreatment total score and age for patients with MDD and healthy controls
Left hippocampus Right hippocampus
Beta T P-value Beta T P-value
Patients
GILZ mRNA 0.59 3.4 0.002 0.57 3.3 0.003
GR mRNA  0.05  0.29 0.77  0.03  0.16 0.87
IL-6  0.44  2.1 0.044  0.44  2.1 0.046
CRP 0.42 2.0 0.051 0.38 1.8 0.08
Childhood maltreatment total score 0.17 0.97 0.34 0.01 0.06 0.95
Age 0.14 0.81 0.43 0.24 1.3 0.20
Healthy subjects
GILZ mRNA  0.13  0.62 0.54  0.16  0.75 0.46
GR mRNA 0.08 0.34 0.74 0.03 0.15 0.89
IL-6 0.05 0.30 0.77  0.16  0.89 0.38
CRP  0.17 1.0 0.32 0.38 1.8 0.08
CTQ total score 0.07 0.40 0.69 0.02 0.11 0.91
Age  0.15 0.80 0.43  0.21  1.2 0.25
Abbreviations: CRP, C-reactive protein; CTQ, Childhood Trauma Questionnaire; IL, interleukin; GILZ, glucocorticoid-inducible genes Leucin Zipper; GR,
glucocorticoid receptor; MDD, major depressive disorder.
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could show that childhood maltreatment signiﬁcantly predicts
higher CRP levels later in life and has a tendency to predict
higher IL-6 levels. These ﬁndings are in line with previous
studies: childhood maltreatment was positively associated
with overall change in plasma IL-6 response, as well as the
maximum IL-6 concentration during the Trier Social Stress
Test (TSST) in 69 healthy adults
38 and with the CRP
concentration in a life-course study cohort of 972 partici-
pants.
39 Moreover, male patients with increased early life
stress had higher IL-6 responses to the TSST.
40 Thus, it was
also interesting to look at the association between these
inﬂammatory proteins and hippocampal and amygdala
volumes. In the regression model, we found that increased
IL-6 plasma concentration was associated with smaller
hippocampal volumes, which underlines the role of inﬂamma-
tion in the model of stress-toxicity also in humans.
Recently, along with others, we reported that childhood
maltreatment negatively affects hippocampal volumes in
MDD.
41–44 In this study, we could show that childhood
maltreatment is associated with increased inﬂammation,
which, in turn, is associated with smaller hippocampal
volumes. The fact that childhood maltreatment does not
directlypredicthippocampalvolumes,isnotincontradictionto
a hypothetical model in which childhood maltreatment might
resultinhigherinﬂammationandglucocorticoiddysregulation,
which then might result in smaller hippocampal volumes over
time. As the effects of GILZ and SGK-1 mRNA expression on
hippocampal volumes were seen in the patient group only,
likely other current or vulnerability factors, for example, like
geneticfactors,associatedwith depressionmightbeimportant
additional factors to consider that we did not analyze in this
study. Environmental factors like stress and genetic variation
are linked together via epigenetic processes. Patients with
MDD show smaller hippocampal volumes when they had a
history of early life adversity and when they carried the short
(S) risk allele of a serotonin transporter variant (5-HTTLPR).
45
Theamygdalawas notdifferentbetweenpatients withMDD
compared with HC. Subsequently, the mix in depressed
samples with regards to inﬂammation and cortisol dysregula-
tion could be the reason for inconsistent ﬁndings with respect
to amygdala volumes leading to no signiﬁcant differences in
the aggregate.
46 Higher IL-6 concentrations and higher
expression of SGK-1 were associated with larger amygdala
volumes.
Toovercometheissueofmultipletesting,weusedomnibus
ANOVA designs followed by post-hoc Sidak–Bonferroni tests
for multiple testing. Also the sample size with 40 patients and
43 controls was reasonable for an imaging study looking at
objective correlations with blood markers, for more in detail
interactive analyses between diagnostic groups, glucocorti-
coid proﬁle and childhood maltreatment a larger group size
would have been preferable. A limitation might be that 2/3 of
ourpatientswerecurrently onantidepressantmedication, and
the other third came to our service medication-free and were
scanned before a treatment was initiated. However, the
results did not change, when medication status was used
as a covariate in the analysis and actual medication status did
not have an effect on hippocampal volumes or glucocorticoid
or inﬂammation markers. Retrospective assessment of
childhood adversity could be problematic because studies
show that usually childhood trauma remains underreported.
47
We cannot exclude that current depressive symptoms might
result in a negative processing bias, however, since our
patients with depression were not psychotic or otherwise
cognitively disturbed this seems to be rather unlikely.
Based on these ﬁndings, we suggest that reduced expres-
sion of glucocorticoid-responsive genes like GILZ as well as
increased inﬂammation may have a role in the neuroplasti-
city–neurotoxicity cascade. Based on our ﬁndings, we could
argue that reduced glucocorticoid responsiveness and in-
creased inﬂammation seem to be associated with reduced
hippocampalvolumesinpatientswithMDDandthatthismight
form a subgroup of patients who could beneﬁt from
therapeutic strategies preventing stress-related neuronal
change, for example, b-adrenergic receptor antagonism
prevented the stress-induced changes in microglia and
macrophages in areas like the hippocampus.
21 The present
ﬁnding strengthens evidence that peripheral inﬂammatory
measures and peripheral measures of GR expression/
function can provide useful information regarding events
occurring in the central nervous system.
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